Benefits of early hepatitis B immunization programs for newborns and infants

Pediatric Infectious Disease Journal

Volumn 27, Issue 10, 2008, Pages 861-869

  Van Herck, Koen ^a,b   Van Damme, Pierre ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b RESEARCH FOUNDATION FLANDERS FWO   (Belgium)

Author keywords

Hepatitis B vaccination; Public health; Universal immunization; Vaccination programs

Indexed keywords

HEPATITIS B VACCINE;

ADOLESCENT HEALTH; DRUG ABUSE; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; GOVERNMENT; HEPATITIS B; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; NEWBORN; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; VACCINATION COVERAGE; VIRUS CARRIER; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; ADOLESCENT; ARTICLE; DISEASE TRANSMISSION; FEMALE; IMMUNOLOGY; MALE; PREGNANCY; PREVENTIVE HEALTH SERVICE;

ADOLESCENT; DISEASE TRANSMISSION, VERTICAL; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; MALE; PREGNANCY;

EID: 54049155200     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318173966f     Document Type: Note

References (86)

1. Prevention and Control of Perinatal Hepatitis B Virus Transmission in the WHO European Region. Viral Hepatitis Prevention Board Meeting; March 2006; Istanbul. Viral Hepatitis. Dec 2006;15. Available at: www.vhpb.org/files/html/Meetings-and-publications/Viral-Hepatitis-Newsletters/ VH15n1.pdf.
2. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol. 2000;61:362-366.
3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107.
4. Shepard CW, Finelli L, Fiore AE, Bell BP. Epidemiology of hepatitis B and hepatitis B virus infection in United States children. Pediatr Infect Dis J. 2005;24:755-760.
5. Ocama P, Opio CK, Lee WM. Hepatitis B virus infection: current status. Am J Med. 2005;118:1413.
6. Tran TT, Martin P. Hepatitis B: epidemiology and natural history. Clin Liver Dis. 2004;8:255-266.
7. Anonymous. Hepatitis B vaccination in countries with low endemicity. Prescrire Int. 2000;9:213-219.
8. Zimmerman RK, Middleton DB, Burns IT, Clover RD, Kimmel SR. Routine vaccines across the life span, 2005. J Fam Pract. 2005;54(Suppl 1):S9-S26.
9. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 (Revised October 2000). WHO Web site. 2000. Available at: http://who.int/inf-fs/en/fact204.html.
10. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34:1329-1339.
11. World Health Organization. Vaccines and Biologicals. WHO vaccine preventable disease monitoring system. Global summary 2006 (data up to 2005). Available at: http://www.who.int/vaccines-documents/GlobalSummary/GlobalSummary. pdf.
12. Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J. Med. Virol. 2002;67: 433-439.
13. The Centers for Disease Control (CDC). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee. MMWR Recomm Rep.1991; 40:1-25.
14. World Health Organization. Expanded programme on immunization. Global Advisory Group-Part I. Wkly Epidemiol Rec. 1992;67:11-15.
15. Banatvala J, Van Damme P, Emiroglu N. Hepatitis B immunisation in Britain: time to change? Brit Med J. 2006;332:804-805.
16. Centers for Disease Control and Prevention. Recommendation of the Immunization Practices Advisory Committee (ACIP) Inactivated Hepatitis B Virus Vaccine. MMWR Morb Mortal Wkly Rep. 1982;31:317-322, 327-328.
17. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. J Am Med Assoc. 1990;263:1218-1222.
18. Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board. Br Med J. 1997;314:1033-1036.
19. Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol. 2006;78:169-177.
20. Van Herck K, Leuridan E, Van Damme P. Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance. Sex Transm Infect. 2007;83:426-432.
21. Mansoor OD, Salama P. Should hepatitis B vaccine be used for infants? Expert Rev Vaccines. 2007;6:29-33.
22. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev. 1999;12:351-366.
23. Cutts FT, Hall AJ. Vaccines for neonatal viral infections: hepatitis B vaccine. Expert Rev Vaccines. 2004;3:349-352.
24. World Health Organization. Vaccines and Biologicals. Introduction of hepatitis B vaccine into childhood immunization services. Management guidelines, including information for health workers and parents. (WHO/V&B/01.31) 2001. Available at: http://www.who.int/vaccines-documents/.Accessed April 26, 2006.
25. Marion SA, Tomm Pastore M, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol. 1994;140:734-746.
26. Pichichero ME, Blatter MM, Reisinger KS, et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J. 2002;21:854-859.
27. Ota MO, Vekemans J, Schlegel-Haueter SE, et al. Influence of Myco-bacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol. 2002;168:919-925.
28. World Health Organization. Hepatitis B vaccines. WHO Position Paper. Wkly Epidemiol Rec. 2004;28:255-263.
29. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. Brit Med J. 2006;332:328-336.
30. EUROHEP.NET: surveillance of vaccine-preventable hepatitis. Available at: www.eurohep.net. Accessed March 11, 2008.
31. Andre FE, Zuckerman AJ. Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol. 1994;44:144-151.
32. Mast E, Margolis H, Fiore A, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: immunization of infants, children, and adolescents. MMWR. 2005;54(RR-16):1-23.
33. Anderson TA, Wexler DL. States report hundreds of medical errors in perinatal hepatitis B prevention. St. Paul, MN: Immunization Action Coalition; 2005. Available at: http://www.immunize.org/catg.d/p2062.htm.
34. Thomas AR, Fiore AE, Corwith HL, Cieslak PR, Margolis HS. Hepatitis B vaccine coverage among infants born to women without prenatal screening for hepatitis B virus infection: effects of the joint statement on thimerosal in vaccines. Pediatr Infect Dis J. 2004;23: 313-318.
35. Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule-United States, 2006. MMWR. 2005;54 (51/53):Q1-Q4.
36. Viral Hepatitis Prevention Board. Hepatitis B as a community health risk. VHPB meeting, Antwerp, Belgium, July 1995. Viral Hepatitis. 1995;4:2.
37. MacIntyre CR. Hepatitis B vaccine: risks and benefits of universal neonatal vaccination. J Paediatr Child Health. 2001;37:215-217.
38. Kane MA. Global status of hepatitis B immunisation. Lancet. 1996;348: 696.
39. Whittle HC, Maine N, Pilkington J, et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet. 1995;345:1089-1092.
40. Koff RS. Hepatitis vaccines: recent advances. Int JParasitol. 2003;33: 517-523.
41. Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs. 2003;63:1021-1051.
42. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA. 1996;276:906-908.
43. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336: 1855-1859.
44. Hepatitis B immunization coverage in the WHO European region 1990 -2004. WHO Europe programme on vaccine-preventable diseases and immunization. Data collected using the WHO/United Nations Children's Fund (UNICEF) joint reporting form. Available at: http://data.euro.who.int/cisid/.
45. Vryheid RE, Kane MA, Muller N, Schatz GC, Bezabeh S. Infant and adolescent hepatitis B immunization up to 1999: a global overview. Vaccine. 2000;19:1026-1037.
46. Centers for Disease Control and Prevention (CDC). National, state, and urban area vaccination coverage among children aged 19-35 months, United States, 2004. MMWR Morb Mortal Wkly Rep. 2005; 54:717-721.
47. Schmitt HJ, Booy R, Weil-Olivier C, Van Damme P, Cohen R, Peltola H. Child vaccination policies in Europe: a report from the summits of independent European vaccination experts. Lancet Infect Dis. 2003;3: 103-108.
48. World Health Organization-Europe. Vaccine-preventable Diseases and Immunization Programme. Regional Immunization Programme Managers' Meeting. Report of WHO meeting, Rogaska Slatina, Slovenia, 18 -20 October 2004. Available at: http://www.euro.who.int/document/E86868.pdf. Accessed May 9, 2006.
49. Poovorawan Y. Experience of combined tetravalent diphtheria, tetanus, whole-cell pertussis and hepatitis B vaccine in Thailand. Southeast Asian J Trop Med Public Health. 28:496 -499.
50. Poovorawan Y, Theamboonlers A, Sanpavat S, Chongsrisawat V, Willems P, Safary A. Comparison study of combined DTPw-HB vaccines and separate administration of DTPw and HB vaccines in Thai children. Asian Pac JAllergy Immunol. 1999;17:113-120.
51. Banatvala JE, Van Damme P. Hepatitis B vaccine-do we need boosters? J Viral Hepat. 2003;10:1-6.
52. Safary A, Andre F. Over a decade of experience with the yeast recom-binant hepatitis B vaccine. Vaccine. 1999;18:57.
53. Niu MT. Review of 12 million doses shows hepatitis B vaccine safe. Vaccine Weekly. 1996;4:13-15.
54. Francois G, Duclos P, Margolis H, et al. Vaccine safety controversies and the future of vaccination programs. Pediatr Infect Dis J. 2005;24: 953-961.
55. Venters C, Graham W, Cassidy W. Recombivax-HB: perspectives past, present and future. Expert Rev Vaccines. 2004;3:119-129.
56. Mast E, Mahoney F, Kane M, Margolis H. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Orlando, FL: WB Saunders Co.; 2003:299-337.
57. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J. 2004;23:650-655.
58. Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366:1379-1384.
59. FitzSimons D, Francois G, Hall A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine. 2005;23:4158-4166.
60. Poovorawan Y, Chongsrisawat V, Hutagalung Y, Srinavasa K, Hoet B. Long-term efficacy of hepatitis B vaccination of newborns born of hepatitis B surface antigen-positive mothers in Thailand [abstract]. 12th International Symposium on Viral Hepatitis and Liver Disease; July 1-5, 2006; Paris.
61. Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, Safary A. Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch Dis Child Fetal Neonatal Ed. 1997;77:F47-F51.
62. Pooverawan Y, Sanpavat S, Theamboonlers A, Safary A. Long-term follow-up (11 to 13 years) of high-risk neonates, born to hepatitis B e antigen-positive mothers and vaccinated against hepatitis B. Proceedings of 10th International Symposium Viral Hepatitis Liver Disease. 2002;263-266.
63. Lolekha S, Warachit B, Hirunyachote A, Bowonkiratikachorn P, West DJ, Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine. 2002;20:3739-3743.
64. Boxall EH, A Sira J, El-Shuhkri N, Kelly DA. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis. 2004;190:1264-1269.
65. Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Br Med J. 2002;325:569.
66. Wu JS, Hwang LY, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants: 10-year follow-up. J Infect Dis. 1999;179:1319-1325.
67. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 2000;19:877-885.
68. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet. 2000; 355:561-565.
69. World Health Organization. Hepatitis B vaccine. Available at: www. who.int/vaccines/en/hepatitisb.html. Accessed April 2006.
70. Recommendations of the Immunization Practices Advisory Committee (ACIP). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40:1-25.
71. Lu CY, Chiang BL, Chi WK, et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology. 2004;40:1415-1420.
72. Viral Hepatitis Prevention Board. Combined hepatitis B vaccines. Viral Hepatitis Prevention Board meeting. Viral Hepatitis. 2002;10.2. October 22-23, 2001; St Julians, Malta.
73. Schmitt HJ. Factors influencing vaccine uptake in Germany. Vaccine. 2001;20(Suppl 1):S2-S4.
74. Denis F, Abitbol V, Aufrere A. Evolution of strategy and coverage rates for hepatitis B vaccination in France, a country with low endemicity. Med Mal Infect. 2004;34:149-158.
75. Bramley JC, Wallace LA, Ahmed S, et al. Universal hepatitis B vaccination of UK adolescents: a feasibility and acceptability study. Commun Dis Public Health. 2002;5:318-320.
76. Zuckerman J, Langer B. Hepatitis B vaccination in a school age population: a feasibility study. J Med Virol. 2005;76:47-54.
77. Slonim AB, Roberto AJ, Downing CR, et al. Adolescents' knowledge, beliefs, and behaviors regarding hepatitis B: Insights and implications for programs targeting vaccine-preventable diseases. J Adolesc Health. 2005;36:178-186.
78. Centers for Disease Control and Prevention (CDC). Hepatitis B vaccination coverage among Asian and Pacific islander children-United States, 1998. MMWR Morb Mortal Wkly Rep. 2000;49:616-619.
79. Navarro Alonso JA, Bernal Gonzalez PJ, Niguez Carbonell JC. Analysis of factors influencing vaccine uptake: perspective from Spain. Vaccine. 2002;20:S13-S15.
80. Swennen B, Van Damme P, Vellinga A, Coppieters Y, Depoorter AM. Analysis of factors influencing vaccine uptake: perspective from Belgium. Vaccine. 2002;20:S5-S7.
81. Bonanni P, Bergamini M. Factors influencing vaccine uptake in Italy. Vaccine. 2002;20:S8-S12.
82. Orenstein WA, Hinman AR. The immunization system in the United States-The role of school immunization laws. Vaccine. 1999;17:S19-S24.
83. Immunization Action Coalition. Hepatitis B prevention mandates. St. Paul, MN: Immunization Action Coalition; 2005. Available at: http://www.immunize.org/ laws/hepb.htm.
84. Kollar LM, Rosenthal SL, Biro F. Hepatitis B vaccine series compliance in adolescents. Pediatr Infect Dis J. 1994;13:1006-1008.
85. Immergluck LC, Williams FE, McCarthy CA. Evaluation of the acceptance of the hepatitis B vaccination in urban adolescents [abstract]. Arch Pediatr Adolesc Med. 1994;148(Suppl):120.
86. Wong VK, Woodruff C, Shapiro R. Compliance of hepatitis B vaccination in patients presenting to a teenage clinic. Pediatr Infect Dis J. 1994;13:936.